Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRISM: Targeted Agents + Acalabrutinib in R/R Aggressive NHL
NCT03527147Phase 1Completed
- Sponsor
- Acerta Pharma
- Start
- Jun 2018
- Primary completion
- Mar 2021
- Modality
- Prophylactic Vaccines, Monoclonal Antibodies, Modified DNA Oligonucleotides
- Countries
- 2
01
Overview
Phase 1, open-label trial of danvatirsen, ceralasertib, magrolimab, AZD5153 and acalabrutinib tablet (Variant 1) in non-Hodgkin lymphoma (NHL) (4 arms), sponsored by Acerta Pharma. Primary endpoint: Incidence of adverse events at 1 year. Started Jun 2018; status: completed.
02
Drugs
danvatirsenceralasertibmagrolimabAZD5153acalabrutinib tablet (Variant 1)
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT03527147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03527147.